Provided by Tiger Trade Technology Pte. Ltd.

Galmed Pharmaceuticals

4.31
+0.25536.30%
Post-market: 4.450.1447+3.36%16:07 EDT
Volume:40.17K
Turnover:176.18K
Market Cap:4.48M
PE:-0.27
High:4.49
Open:4.08
Low:3.96
Close:4.05
52wk High:13.20
52wk Low:3.29
Shares:1.04M
Float Shares:1.01M
Volume Ratio:0.45
T/O Rate:3.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.1401
EPS(LYR):-19.1292
ROE:-72.12%
ROA:-33.45%
PB:0.32
PE(LYR):-0.23

Loading ...

Galmed Pharmaceuticals Ltd Expected to Post a Loss of $3.12 a Share - Earnings Preview

Reuters
·
Aug 24

Galmed Amends AGM Proxy Materials Ahead of Sept. 2 Shareholder Vote

Reuters
·
Aug 20

Colospan completes feasibility study of new assesment platform

TIPRANKS
·
Aug 19

Galmed Says Colospan Intraoperative Colon Tissue Assessment Study Meets Feasibility Goal in First-in-Human Trial

Reuters
·
Aug 19

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

THOMSON REUTERS
·
Aug 19

Galmed trading halted, news pending

TIPRANKS
·
Aug 19

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Aug 19

Galmed reports results from study of a combination of Aramchol and Xtandi

TIPRANKS
·
Aug 17

Galmed Says Aramchol-Xtandi Combo Lifts Prostate Cancer Cell Death 3-4 Fold in Preclinical Study

Reuters
·
Aug 17

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (Xtandi®) Alone in Prostate Cancer Models

THOMSON REUTERS
·
Aug 17

Galmed Pharmaceuticals to Execute 1-for-8 Reverse Share Split Aug. 19, 2026

Reuters
·
Aug 15

Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance

TIPRANKS
·
Aug 01

Galmed Pharmaceuticals: as a Result of Termination, All Rights to Licensed Technology Will Revert to Yissum

THOMSON REUTERS
·
Jul 30

Galmed Pharmaceuticals: Co's Unit's Obligation to Fund Ongoing Patent Expenses Relating to Licensed Patents Will Cease Effective July 31

THOMSON REUTERS
·
Jul 30

Galmed Pharmaceuticals: Co's Unit & Yissum Entered into Mutual Termination Letter to Terminate License Agreement, Dated June 28, 2021

THOMSON REUTERS
·
Jul 30

Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s

TIPRANKS
·
Jul 28

Galmed Says Aramchol Oral Film Boosts Bioavailability 150%, CNS Exposure 300% in Parkinson’s Program

Reuters
·
Jul 28

Galmed Pharmaceuticals Unveils Cardiac-Targeted Aramchol LNP Breakthrough

TIPRANKS
·
Jul 17

Galmed Partners with Barcode Nanotech on Heart-targeted Aramchol LNP Formulation

Reuters
·
Jul 16

Galmed Announces the Breakthrough Development of Novel Lnp Cardiac Targeted Formulation of Its Scd1 Inhibitor, Aramchol

THOMSON REUTERS
·
Jul 16